IJCS | Volume 33, Nº3, May / June 2020

238 Table 2 - Surgery characteristics Bovine UH treated N = 204 Porcine UH treated N = 65 Total N = 269 Most frequent type of surgery Coronary artery bypass grafting 111 (54.41) 27 (41.54) 138 (51.30) Aortic valve replacement 20 (9.80) 12 (18.46) 32 (11.90) Coronary artery bypass grafting and aortic valve replacement 11 (5.39) 8 (12.31) 19 (7.06) Mitral valve replacement 10 (4.90) 6(9.23) 16 (5.95) Left ventricular aneurysmectomy and coronary artery bypass grafting 9 (4.41) 1 (1.54) 10 (3.72) Atrioseptoplasty (correction of interatrial communication) 2 (0.98) 2 (3.08) 4 (1.49) Bentall D’Bono surgery 3 (1.47) 1 (1.54) 4 (1.49) Coronary artery bypass grafting and aortic valve replacement and mitral valve replacement 4 (1.96) 0 4 (1.49) Mitral valve repair 3 (1.47) 0 3 (1.12) Surgery duration Median 297.5 230.0 270.0 Min–max (120–540.0) (100.0–475.0) (100.0–540.0) Q1–Q3 240.0–330.0 180.0–255.0 222.0–330.0 ECC duration Median 89.0 86.0 88.0 Min–max (35.0–273.0) (30.0–169.0) (70.0–110.0) Q1–Q3 72.0–111.0 69.0–110.0 70.0–110.0 Qualitative variables are shown as n (%) and quantitative variables as median, minimum and maximum values, interquartile range. Duration is shown as minutes. Q1: percentile 25%; Q3: percentile 75%. ECC: extracorporeal circulation. Source: prepared by the authors. Lima et al. Unfractionated bovine heparin safety Int J Cardiovasc Sci. 2020; 33(3):235-242 Original Article Activated clotting time (ACT) values Table 4 shows themedianACT before, during and after ECC (after protamine administration) in both groups. Heparin dosage Patients received a median dose of 288 mg bovine UFH before ECC, ranging from 120 to 520 mg. The total dose used ranged from 172 mg to 550 mg, with a median of 320 mg. Patients treated with porcine UFH received initial doses between 124 mg and 452 mg, with a median dose of 288.5 mg. The total dose ranged from 200 to 454 mg, with a median dose of 317 mg. Protamine dosage In the group treated with bovine UFH, the initial dose of protamine administered ranged from 65 mg to 900 mg, with a median dose of 500 mg. Some patients (23.5%) received an additional dose of protamine with a median dose of 100 mg, ranging from 50 to 600 mg. For participants receiving porcine UFH, the initial protamine dose ranged from 300 to 700 mg, with a median dose of 500 mg, with an additional treatment in 35.4% of patients (median dose of 100 mg, ranging from 50 to 200 mg). Discussion Heparin is the anticoagulant routinely used during ECC with the advantage of lower allergy risk and an easily reversible effect through protamine. 13 However, bleeding is the most known, severe and expected adverse effect. Excessive postoperative bleeding generates higher incidence of infectious complications and higher